科伦博泰生物在港交所公告,公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT)(佳泰莱®)的一项新增适应症上市申请已获国家药监局(NMPA)药品审评中心(CDE)受理,用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性(HR+)且人表皮生长因子受体2阴性(HER2-)乳腺癌(BC)成人患者。该申请是芦康沙妥珠单抗获NMPA受理的第四个适应症上市申请。
(文章来源:人民财讯)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.